Insider Buying: Scancell Holdings plc (LON:SCLP) Insider Acquires 44,944 Shares of Stock

Scancell Holdings plc (LON:SCLP) insider Martin Diggle purchased 44,944 shares of the firm’s stock in a transaction on Tuesday, May 20th. The stock was acquired at an average cost of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,417.12).

Scancell Stock Up 8.8%

Shares of LON:SCLP opened at GBX 10.06 ($0.13) on Wednesday. The stock’s 50-day moving average price is GBX 9.32 and its two-hundred day moving average price is GBX 10.24. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. Scancell Holdings plc has a 12-month low of GBX 7.26 ($0.10) and a 12-month high of GBX 19.75 ($0.26). The firm has a market cap of £104.19 million, a price-to-earnings ratio of -15.42 and a beta of 0.35.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.